ValuEngine Upgrades Checkpoint Therapeutics (NASDAQ:CKPT) to “Buy”

Checkpoint Therapeutics (NASDAQ:CKPT) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

A number of other research firms have also recently weighed in on CKPT. HC Wainwright increased their price objective on Checkpoint Therapeutics from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Lake Street Capital assumed coverage on Checkpoint Therapeutics in a research report on Wednesday, May 29th. They set a “buy” rating for the company.

Checkpoint Therapeutics stock traded down $0.34 during mid-day trading on Thursday, reaching $2.29. 79,900 shares of the company were exchanged, compared to its average volume of 92,812. Checkpoint Therapeutics has a twelve month low of $1.50 and a twelve month high of $5.20. The stock has a 50-day moving average price of $3.26. The stock has a market capitalization of $94.75 million, a price-to-earnings ratio of -1.80 and a beta of 3.12.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. Checkpoint Therapeutics had a negative return on equity of 211.99% and a negative net margin of 952.83%. The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. Analysts forecast that Checkpoint Therapeutics will post -0.64 EPS for the current fiscal year.

An institutional investor recently bought a new position in Checkpoint Therapeutics stock. Park Avenue Securities LLC bought a new position in shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,593 shares of the company’s stock, valued at approximately $199,000. Park Avenue Securities LLC owned approximately 0.19% of Checkpoint Therapeutics at the end of the most recent quarter. Institutional investors own 8.52% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.

Further Reading: What is the Current Ratio?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.